Phase 2
PIPE-307: Phase 2 VISTA missed its efficacy endpoints
In relapsing-remitting MS, VISTA reported acceptable safety and tolerability, but PIPE-307 did not meet its prespecified primary or secondary efficacy endpoints.
What this means clinically
One of the most discussed remyelination-specific compounds did not demonstrate clinical efficacy in Phase 2; further MS development remains uncertain.
Source quality: High for topline status • official SEC filing, not a peer-reviewed full paper
Company filingContineum / SEC filing ↗